| Methods |
4‐week placebo run‐in; inclusion criteria= sitting DBP 100‐110 mm Hg at end of run‐in; 8‐week double‐blind treatment |
| Participants |
Trandolapril 1 mg: n=50; mean age=51(10) years; baseline sitting SBP=159.3(12.4) mm Hg, DBP=103.6(3.1) mm Hg, HR=73.2(10.6) bpm;
Placebo: n=51; mean age=52(9) years; baseline sitting SBP=158.2(13.5) mm Hg, DBP=103.5(3.4) mm Hg, HR=75.4(8.2) bpm |
| Interventions |
Trandolapril 1 mg once daily;
Placebo;
administered at approximately 9 AM after breakfast |
| Outcomes |
Trough sitting SBP/DBP using mercury sphygmomanometer;
Peak sitting SBP/DBP using mercury sphygmomanometer;
Trough sitting HR;
WDAE |
| Notes |
BP change and SD of change not reported; endpoint BP and SD reported; imputed endpoint SD for SD of change; trough BP data from Table 1, p. 493; peak BP data (using 24h ambulatory BP monitoring) in Figure 3, p. 496; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
